Drug intelligence / Profile preview

ACH-0137171

Development stage: Discontinued
Lead developer: Alexion Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

ACH-0137171 is a small molecule drug that was initially developed by Alexion Pharmaceuticals for the treatment of chronic hepatitis C virus (HCV) infection. The drug advanced to Phase 2 clinical trials, where it was evaluated for its safety, tolerability, pharmacokinetics, and antiviral activity in patients with chronic HCV. The development of ACH-0137171 has since been discontinued and it is no longer in active clinical development. Its mechanism of action and molecular target have not been publicly disclosed[1][2][3].

Beyond the preview

Go deeper on ACH-0137171.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACH-0137171.

Explore the full profile